17/06/2009 · Nike Marketing Case Study
Susan Baldwin is a Senior Scientist and Principal Investigator at IDRI. Dr. Baldwin has been at IDRI for over six years and currently works on projects related to development of next-generation vaccines against infectious diseases. Her research involves preclinical immunology and efficacy of vaccines against H5N1 pandemic influenza, malaria, and Mycobacterium tuberculosis using mouse, ferret and guinea pig models.
June 17, 2009 at 11:42 am Leave a comment
Before joining IDRI, Ryan was a postdoctoral fellow at the Macromolecule and Vaccine Stabilization at the University of Kansas, under the supervision of Russ Middaugh and David Volkin. He worked on over 12 contract and research formulation development projects characterizing different macromolecular systems and biotherapeutics, using state of the art analytical biophysical instrumentation.
Thomas Vedvick is the Vice President of Formulation and Process Development at IDRI. Tom's research interests are focused on the development of large scale protein purification and the characterization of proteins for vaccine development. In addition, Tom directs the exciting adjuvant formulation program at IDRI. He has more than 70 original articles, and holds 28 issued U.S. patents for diagnostics, vaccines, and therapeutics of infectious diseases and cancer.
25/06/2017 · How big is Nike
Erik Iverson is Managing Director of WARF (Wisconsin Alumni Research Foundation). Prior to joining WARF in 2016, Erik served as President, Business & Operations at IDRI. Prior to joining IDRI, Erik was Associate General Counsel at the Bill & Melinda Gates Foundation, where he was the second attorney on staff and worked for over seven years exclusively within the Foundation's Global Health Program, where he led the development and implementation of the foundation's Global Access policy through the review of grant proposals and assistance in structuring strategic initiatives. More particularly, Erik worked closely with foundation staff and grantees in the development of intellectual property management and collaboration agreements, novel financing arrangements, and product development and "global access" strategies. Previously, Erik was an attorney at the law firm of Perkins Coie LLP, where he represented life science companies in the negotiation of financing transactions, joint ventures, research collaborations, licensing arrangements, and manufacturing agreements. Erik received his JD from the University Of North Dakota School Of Law in 1994 and his Masters of Law (LLM) in Taxation from New York University School of Law in 1995.
What is Nike's market share, and what are Nike's sales statistics
Gail H. Cassell, Executive Vice President of TB Drug Development, IDRI, is also a Visiting Professor in the Department of Global Health and Social Medicine at Harvard Medical School. Gail recently retired as Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases at Eli Lilly and Company in Indianapolis where she was responsible for launching the Lilly MDR-TB philanthropic effort and establishing and leading the Lilly TB Drug Discovery Initiative, a nonprofit launched in 2007. Formerly she was Vice President of Infectious Diseases Drug Discovery and Clinical Development at Lilly, where she led a hepatitis C protease inhibitor program from the discovery phase to clinical candidate, and the development of a new antibiotic from clinical development to product decision. Prior to Lilly, Gail served as the Charles H. McCauley Professor and Chairman of the Department of Microbiology at the University of Alabama Schools of Medicine and Dentistry at Birmingham.
Nike, Inc. - NKE - Stock Price Today - Zacks
Prior to joining Sanofi Pasteur, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) in Belgium. He joined the group in 1978 as a research scientist and subsequently held positions of increasing responsibility to become Vice President, Research & Development, heading a team active in all aspects of preclinical vaccine development.